Beyond "$X Off Botox": Why Consultation-First Marketing Fits Today's Med Spa Market

Another "$X off Botox" promotion will not set your Med Spa apart.

By one industry estimate, the U.S. now has more than 10,000 Med Spa locations, all competing for the same patients. At the same time, regulators are looking harder at how treatments are prescribed, supervised, and promoted. This week's market news points to the same answer from both directions: lead with the patient's goals, and make the clinical steps clear.

Here are four developments worth knowing about.

Lead with the patient's desired outcome, offer a comprehensive assessment, and send every clinical question to licensed staff.

1. FDA scrutiny of compounded GLP-1 prescribing is tightening

On September 24, the American Med Spa Association analyzed an FDA warning letter concerning compounded semaglutide and tirzepatide after the drug shortages ended. According to that analysis, the FDA challenged prescriptions that lacked patient-specific justification or relied on nearly identical "medical necessity" statements. It also noted that simply adding B12 or another ingredient does not automatically justify compounding, and that lower cost is generally not enough.

In our view, owners should no longer treat compounded GLP-1s as a broad, interchangeable alternative to approved products. Advertising and automated replies should never suggest that every prospect qualifies. Eligibility and prescribing are clinical decisions that a licensed provider makes patient by patient.

Worth reviewing:

• GLP-1 landing pages and follow-up messages, looking for blanket eligibility, availability, savings, or "custom formula" claims.
• Whether medication and eligibility questions always go to a licensed provider, rather than to a script that recommends a formulation.
• Whether your documentation would hold up under a patient-by-patient review. Your counsel and medical director can help with that question.

This is general education, not legal or medical advice.

2. Comprehensive consultations are becoming a retention strategy

Allergan Aesthetics launched its AA Signature: SKIN360 consultation approach on September 22. It combines a structured facial assessment with multiple treatment categories. Allergan cites company-supported research suggesting strong consumer interest in comprehensive consultations and higher retention among practices that use multimodal planning. Those figures should be read as manufacturer-supported findings. The company also states that the safety and effectiveness of the featured products used in combination have not been studied.

In our view, the direction is clear: the industry is moving from selling isolated procedures toward personalized treatment journeys. For follow-up, that means starting a conversation about goals instead of pushing a product right away.

Ideas to consider:

• Build campaigns around a comprehensive assessment, not only discounted single treatments.
• Organize follow-up around the patient's goals, such as skin quality, facial balance, or healthy aging.
• Invite prospects to start with a plan designed around their goals, instead of a treatment chosen from a menu.
• Leave every treatment recommendation to your providers.

3. Crowded markets make positioning more valuable than promotions

A September 25 AmSpa marketing article estimates that the U.S. Med Spa market has grown from roughly 1,600 locations in 2010 to more than 10,000 today. It argues that similar service menus push prospects to compare price, location, and promotional offers. Those estimates and recommendations come from an industry consultant, not an independent census.

Generic discount campaigns may attract price shoppers without giving them a reason to stay. Before buying more traffic, it helps to be sure there is a clear, defensible reason to choose your practice.

Questions to answer first:

• Who is your ideal patient?
• Which treatment category is your strongest?
• What makes you different from the nearest competitor?
• What gives people a reason to believe it?

A simple exercise: ask three employees and three patients, separately, "Why choose this practice instead of the nearest competitor?" Then compare the answers. The gaps are often the most useful part.

4. States continue reconsidering supervision and delegation rules

Utah's licensing-review office presented recommendations addressing Med Spa definitions, provider evaluations, treatment plans, delegation, supervision, and wellness injections. These are recommendations, not current law. AmSpa notes, however, that they reflect regulatory questions emerging in multiple states.

Growth campaigns can expose operational weaknesses if they promote treatments faster than the practice can provide proper evaluation and supervision. In our view, no single workflow fits every state.

Questions to put in front of your team and your counsel:

• Which state's rules apply, and who is the treating provider?
• What evaluation is required before treatment?
• Who approves each treatment plan?
• Can your Med Spa legally deliver every treatment it advertises?

Make clinical eligibility and treatment-plan approval clear handoffs to a human in any follow-up workflow, automated or not.

The takeaway

A consultation-first campaign answers three pressures at once: more competition, stronger demand for personalized care, and closer regulatory attention. Here is the structure in five steps:

• Lead with the patient's desired outcome.
• Offer a comprehensive assessment.
• Use automation for immediate contact and scheduling.
• Send clinical questions to licensed staff.
• Measure completed consultations, treatment acceptance, and repeat bookings.

This article is general education, not legal or medical advice. Elite Med Spa Solutions is a growth partner, not a law firm. Talk with qualified healthcare counsel and your medical director about what your practice may offer and how it may be advertised.

If you want to book more appointments with an automated AI system built around responsible, accountable follow-up, book a FREE, no obligation strategy call. Visit EliteMedSpaSolutions.com to get started.

Sources

• American Med Spa Association (AmSpa), September 24, 2026, analysis of an FDA warning letter on compounded semaglutide and tirzepatide.
• Allergan Aesthetics, September 22, 2026, launch of AA Signature: SKIN360.
• American Med Spa Association (AmSpa), September 25, 2026, marketing article on the U.S. Med Spa market.
• American Med Spa Association (AmSpa), coverage of Utah licensing-review office recommendations on Med Spa supervision and delegation.

Details above are summarized from these publications. Market estimates come from an industry consultant, and company research figures come from the manufacturer. Please review the original sources for the most current information.